secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276424
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022
------------------------------------------------------------------------

- Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.
- R&D expenses $68.3M for Q3 2022 vs $54.9M in Q3 2021; G&A $12.1M vs $8.3M.
- Cash used in operations for nine months ended Sep 30, 2022 was $166.3M.
- Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned H1 2023.
- Two resmetirom oral abstracts accepted at AASLD Liver Meeting presenting cirrhosis and noninvasive data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/0001193125-22-276424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/d409333d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer